BCR-ABL by PCR (Quantitative) Test at Lahore PCR Lab

Introduction to BCR-ABL by PCR (Quantitative) at Lahore PCR Lab

The BCR-ABL by PCR (Quantitative) test is a highly sophisticated molecular diagnostic assay designed to detect and quantify the BCR-ABL1 fusion transcript in patients suspected of having or being treated for certain types of leukemia. This test is primarily utilized for individuals diagnosed with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). At Lahore PCR Lab, located in Lahore, Pakistan, this test is performed using state-of-the-art real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) technology. This advanced molecular method offers unparalleled sensitivity and precision, allowing clinical oncologists and hematologists to monitor therapeutic responses at a microscopic level, detect minimal residual disease (MRD), and identify early signs of disease relapse.

The biological basis of this test lies in the detection of a specific genetic abnormality known as the Philadelphia chromosome. This chromosome is formed by a reciprocal translocation between chromosome 9 and chromosome 22, designated as t(9;22)(q34.1;q11.2). This genetic exchange brings together the ABL1 proto-oncogene from chromosome 9 and the BCR gene from chromosome 22, resulting in the creation of the chimeric BCR-ABL1 fusion gene. The protein product of this fusion gene is a constitutively active tyrosine kinase that drives uncontrolled cellular proliferation, inhibits apoptosis, and alters cell adhesion, leading to the characteristic clinical manifestations of leukemia. By quantifying the level of BCR-ABL1 transcripts relative to an endogenous reference gene (such as ABL1), the quantitative PCR assay provides a precise measurement of the leukemic clone burden in the patient's blood or bone marrow.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure sample integrity and accurate molecular results. Patients undergoing the BCR-ABL by PCR (Quantitative) test at Lahore PCR Lab should observe the following guidelines:

• No Fasting Required: Fasting is not necessary for this molecular test. Patients may eat and drink normally prior to sample collection.
• Medication History: It is critical to inform the healthcare provider and laboratory staff of all current medications, particularly tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, nilotinib, bosutinib, or ponatinib, as these therapies directly impact transcript levels.
• Clinical Documentation: Patients should bring their previous hematology reports, including Complete Blood Count (CBC) results, bone marrow biopsy reports, and prior BCR-ABL quantitative PCR results, to facilitate comparative clinical analysis.
• Hydration: Maintaining adequate hydration is recommended to facilitate easier venous access during blood collection.

During the Procedure

The sample collection process is straightforward and adheres to strict clinical and safety protocols to prevent contamination and sample degradation:

• Specimen Type: The test is typically performed on a peripheral blood sample, although bone marrow aspirate samples can also be utilized depending on the physician's request.
• Venipuncture Process: A trained phlebotomist at Lahore PCR Lab will identify a suitable vein, usually in the antecubital fossa of the arm. The area is thoroughly cleansed with an antiseptic solution. A sterile needle is inserted, and blood is collected into a specialized tube containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant (purple-top tube).
• Sample Volume: Approximately 5 to 10 mL of peripheral blood is required to ensure an adequate yield of nucleated cells for RNA extraction.
• Post-Collection Care: After the needle is removed, gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage. Patients can immediately resume their daily activities.
• Specimen Handling: Because RNA is highly susceptible to degradation by ribonucleases (RNases), the collected sample is immediately stabilized and transported to the molecular diagnostics division under controlled temperature conditions to preserve RNA integrity.

When is a BCR-ABL by PCR (Quantitative) Performed?

Diagnosis of Chronic Myeloid Leukemia (CML)

The quantitative BCR-ABL PCR test is performed when a physician suspects Chronic Myeloid Leukemia based on clinical symptoms and abnormal routine blood tests. Patients presenting with persistent, unexplained leukocytosis (elevated white blood cell count) with a full spectrum of myeloid precursors, splenomegaly, and anemia are strong candidates for this test. The assay confirms the presence of the BCR-ABL1 fusion transcript, establishing a definitive molecular diagnosis of CML and distinguishing it from other myeloproliferative neoplasms or reactive leukocytoses.

Monitoring Tyrosine Kinase Inhibitor (TKI) Therapy

For patients diagnosed with CML, the quantitative BCR-ABL test is the cornerstone of therapeutic monitoring. Tyrosine Kinase Inhibitors (TKIs) are targeted therapies that specifically inhibit the abnormal BCR-ABL1 kinase activity. Regular monitoring of BCR-ABL1 transcript levels, typically every 3 months, is recommended by international guidelines (such as the European LeukemiaNet [ELN] and National Comprehensive Cancer Network [NCCN]). This monitoring evaluates the depth of the molecular response, helping clinicians determine if the patient is meeting critical therapeutic milestones.

Detection of Minimal Residual Disease (MRD)

Even when a patient achieves complete hematologic and cytogenetic remission, millions of leukemic cells may still remain in the body, undetectable by standard microscopic evaluation. The quantitative PCR assay is highly sensitive, capable of detecting one leukemic cell among 100,000 or more healthy cells. This extreme sensitivity allows for the detection of Minimal Residual Disease (MRD), providing crucial information regarding the eradication of the leukemic clone and guiding decisions regarding the potential discontinuation of therapy in selected patients who have achieved sustained deep molecular responses.

Diagnosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Approximately 25% to 30% of adult patients with Acute Lymphoblastic Leukemia (ALL) harbor the Philadelphia chromosome. Identifying this genetic subtype is critical because Ph+ ALL carries a distinct prognosis and requires the integration of TKIs into the standard chemotherapy regimen. The quantitative BCR-ABL PCR test is performed at the time of ALL diagnosis to identify the specific transcript type (most commonly the p190 isoform) and to establish a baseline for monitoring treatment efficacy and post-transplant minimal residual disease.

Evaluation of Unexplained Leukocytosis and Splenomegaly

In clinical practice, patients may present with vague symptoms such as persistent fatigue, night sweats, unexplained weight loss, and physical findings like splenomegaly (enlarged spleen). When initial laboratory investigations reveal a significantly elevated white blood cell count with a left shift (presence of immature granulocytes), the quantitative BCR-ABL PCR test is indicated as a primary diagnostic tool to rapidly rule in or rule out a clonal myeloid disorder driven by the BCR-ABL1 oncogene.

What Does a BCR-ABL by PCR (Quantitative) Detect?

The quantitative BCR-ABL PCR test at Lahore PCR Lab evaluates several critical molecular parameters to provide a comprehensive diagnostic profile:

• Presence of BCR-ABL1 Fusion Transcripts: Confirms the qualitative presence of the abnormal fusion gene.
• Quantification of Transcript Levels: Measures the exact ratio of BCR-ABL1 transcripts to control gene transcripts, reported as a percentage.
• International Scale (%IS) Alignment: Standardizes results against the International Scale, allowing direct comparison with global clinical trials and guidelines.
• Major Breakpoint Transcripts (p210): Detects the e13a2 and e14a2 transcript variants, which are characteristic of classic CML.
• Minor Breakpoint Transcripts (p190): Detects the e1a2 transcript variant, commonly associated with Ph+ ALL and occasionally seen in CML.
• Micro Breakpoint Transcripts (p230): Detects the rare e19a2 variant, associated with chronic neutrophilic leukemia.
• Control Gene Copy Number: Measures the copy number of a reference gene (usually ABL1) to ensure the extracted RNA sample is of sufficient quality and quantity for accurate testing.
• Baseline Tumor Load: Establishes the initial quantity of the fusion gene prior to the initiation of targeted therapy.
• Early Molecular Response (EMR): Assesses whether transcript levels have fallen below 10% on the International Scale at the 3-month treatment milestone.
• Major Molecular Response (MMR): Detects whether transcript levels have reached 0.1% IS or lower (equivalent to a 3-log reduction from baseline).
• Deep Molecular Response (DMR – MR4.0): Identifies a 4-log reduction, where BCR-ABL1 transcripts are less than or equal to 0.01% IS.
• Deep Molecular Response (DMR – MR4.5): Identifies a 4.5-log reduction, where BCR-ABL1 transcripts are less than or equal to 0.0032% IS.
• Deep Molecular Response (DMR – MR5.0): Identifies a 5-log reduction, where BCR-ABL1 transcripts are less than or equal to 0.001% IS.
• Molecularly Undetectable Disease: Confirms the absence of detectable BCR-ABL1 transcripts within the limits of assay sensitivity.
• Kinase Domain Mutation Indicators: Identifies a significant rise in transcript levels (e.g., a 1-log increase), which clinically suggests the development of TKI resistance mutations.
• Therapeutic Compliance: Fluctuating or rising transcript levels can indicate potential issues with patient adherence to daily oral TKI therapy.
• Disease Progression Risk: High or rising transcript levels correlate with an increased risk of progression from the chronic phase to the accelerated or blast phase of CML.
• Post-Transplant Chimerism Correlation: Assists in monitoring disease status following an allogeneic stem cell transplant.
• RNA Quality Control: Evaluates sample degradation, ensuring that negative results are truly negative and not due to degraded clinical specimens.
• Efficacy of Novel Therapies: Monitors response to second- and third-generation TKIs in patients who have failed first-line treatment.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely results are critical for oncological decision-making and patient peace of mind. The quantitative BCR-ABL PCR test involves complex molecular steps, including RNA extraction, complementary DNA (cDNA) synthesis, real-time PCR amplification, and meticulous data analysis. Typically, the verified report is available within 3 to 5 working days from the time of sample collection. Lahore PCR Lab provides convenient digital access to diagnostic reports. Patients and referring physicians can securely view, download, and print reports directly from the official website or via SMS notifications containing secure download links, ensuring seamless integration into clinical care pathways.

BCR-ABL Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1/ABL1 Ratio (%IS)	Undetectable (0.000% IS)	Detected (e.g., >10% IS at diagnosis, or rising levels during therapy)
Control Gene Copy Number (ABL1)	High copy number (>10,000 copies) ensuring sample adequacy	Low copy number (<10,000 copies) indicating degraded RNA or inadequate sample
Transcript Type	None detected	Major (p210), Minor (p190), or Micro (p230) transcripts detected
Molecular Response Level (at 3 months)	Not applicable (healthy)	>10% IS (suboptimal early molecular response)
Molecular Response Level (at 12 months & beyond)	Not applicable (healthy)	>0.1% IS (failure to achieve Major Molecular Response)
Trend Analysis	Stable or decreasing levels	Logarithmic increase in transcript levels (suggesting relapse or TKI resistance)
Post-Transplant Status	Undetectable (MRD negative)	Detectable transcripts (MRD positive, high risk of relapse)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for BCR-ABL by PCR (Quantitative)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified molecular pathologists, clinical scientists, and technologists specializing in advanced molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and confidentiality throughout the testing process, from sample collection to report delivery.
• Quality Diagnostic Services: Lahore PCR Lab implements rigorous internal and external quality control protocols to ensure the highest standards of diagnostic accuracy.
• Professional Reporting: Our reports are detailed, structured, and aligned with international clinical standards, providing clear, actionable data for oncologists.
• Modern Diagnostic Approach: We utilize state-of-the-art real-time quantitative PCR technology, ensuring high sensitivity and specificity.
• Comfortable Environment: Our diagnostic center in Lahore offers a clean, modern, and welcoming environment for all patients.
• Convenient Location: Easily accessible within Lahore, Pakistan, facilitating prompt sample drop-off and patient visits.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise molecular insights that are vital for effective cancer management and personalized treatment strategies.